Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
Primary objective: To demonstrate the clinical efficacy of otamixaban (dose effect via 5
intravenous [IV] regimens) in patients with moderate-to-high-risk non-ST elevation acute
coronary syndromes (ACS) and planned early invasive strategy.
Secondary objectives: To evaluate safety and assess pharmacokinetics (PK) and
pharmacodynamics (PD).